Key result
Salidroside prevents epirubicin-induced LV systolic dysfunction, preserving ~20% higher peak strain rate versus placebo.
Why the study?
The cardioprotective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in breast cancer patients have been sparsely investigated.
Does salidroside prevent epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer?
RCT (n=60)
Double-blind
Blind randomization
No
Does salidroside prevent epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer?
Salidroside supplementation may protect against epirubicin-induced early left ventricular regional systolic dysfunction and oxidative stress in patients with breast cancer.
Supports consideration of salidroside to prevent early epirubicin-induced LV dysfunction in breast cancer; extends cardioprotection data for anthracyclines.
Salidroside [2-(4-hydroxyphenyl)ethyl-β-D-glucopyranoside], one of the most potent ingredients extracted from the plant Rhodiola rosea L ., has been shown to have a cardiovascular protective effect as an antioxidant, and early treatment of epirubicin-induced cardiotoxicity has been the focus of clinical chemotherapy in patients with breast cancer. However, the cardioprotective effects of salidroside on epirubicin-induced cardiotoxicity, especially early left ventricular regional systolic dysfunction, have to date been sparsely investigated. The aim of this study was to investigate the protective effects of salidroside in preventing early left ventricular regional systolic dysfunction induced by epirubicin. Sixty patients with histologically confirmed breast cancer were enrolled. Eligible patients were randomized to receive salidroside (600 mg/day; n= 30) or placebo (n = 30) starting 1 week before chemotherapy. Patients were investigated by means of echocardiography and strain rate (SR) imaging. We also measured plasma concentrations of reactive oxygen species (ROS). All parameters were assessed at baseline and 7 days after each new epirubicin dose of 100 mg/m 2 . A decline of the SR peak was observed at an epirubicin dose of 200 mg/m 2 , with no significant differences between salidroside and placebo (1.35 ± 0.36 vs 1.42 ± 0.49/second). At growing cumulative doses of epirubicin, the SR normalized only with salidroside, showing a significant difference in comparison with placebo at epirubicin doses of 300 mg/m 2 (1.67 ± 0.43 vs 1.32 ± 0.53/second, p< 0.05) and 400 mg/m 2 (1.68±0.29 vs 1.40 ± 0.23/second, p < 0.05). Moreover, a significant increase in plasma concentrations of ROS was found with placebo, but they remained unchanged with salidroside. Salidroside can provide a protective effect on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2012) conducted an RCT in Breast cancer (n=60). Salidroside vs. Placebo was evaluated on Strain rate (SR) peak at cumulative epirubicin dose of 400 mg/m2 (p=<0.05). Salidroside prevented epirubicin-induced early left ventricular regional systolic dysfunction, maintaining a significantly higher strain rate peak compared to placebo at a cumulative epirubicin dose of 400 mg/m2 (1.68 vs 1.40/second, p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: